isak55 / shutterstock.com
The IP Life Sciences Exchange, an event for senior IP decision-makers from the life sciences sector, will take place on November 15 and 16 in Munich, Germany. LSIPR previews some of the most interesting sessions.
Session: Strategic steps to take in the wake of uncertain patent eligibility across biopharma
When: 12:45–13:15, November 15
This session kicks off with speakers representing the European Commission, and biotechnology companies Sotio and New England Biolabs. In this session, speakers will assess why it is important to have predictability and uniformity in the global biotech IP sector.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
IP Life Sciences Exchange, Munich, medicine, patent, infringement, Brexit, biopharma